Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
Condition: Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Interventions: Drug: tislelizumab+lenvatinib+GMOX; Drug: tislelizumab+GEMOX Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Gallbladder Cancer | Hospitals | Research